BriaCell Therapeutics
BCTX | NASDAQ
$3.30
-$0.09 (-2.65%)
At close: Nov 16, 2026, 4:00 PM ET
$3.30
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-2.65%
(1D)No price chart data available for 1D timeframe.
Rating
21.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #980/1021 (Top 96%)
Key Statistics
Market Data
Market Cap $28.82M
1D Range
3.29 3.44
52W Range
2.74 12.64
Valuation (TTM)
PE -0.35
PB 1.76
EV/EBITDA -0.23
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $0.00
Cash Flow
FCF Yield -100.0%
SBC Adj. FCF Yield -102.5%
SBC Impact -2.5%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -8.8% |
17.8%
FCF 3Y | 5Y 6.8% |
-11.8%
Returns
ROA -147.3%
ROE -170.7%
ROIC -230.0%
Financial Health
Net Cash
$20.54M
Current Ratio 2.76
Interest Coverage -1,210.23
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is ...
Sector Healthcare
Industry Biotechnology
Employees 16
IPO Date Mar 14, 2012
Website www.briacell.com
Fiscal Year August - July
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove BCTX